Replies to post #9736 on Pluristem Therapeutics Inc (PSTI)

[EichKing]

They compare in the fact they are both being considered (along with CBLI) for the treatment of ARS by the FDA. I believe any EC-18 studies to date were targeted toward neutropenia in humans. I am unaware of red blood cell and platelet restoration outcomes associated with Enzychem study. PSTI has ZERO clinical ARS data in humans, there has been some positive data associated with a pilot study announced last May......PSTI is supposed to conduct a pivotal study sometime in the 21st century.

[Melon4head]

Also remember that they both exhibit 2 different modes of action. One is stem cell, the other not a stem cell. When determining what is the best treatment for a patient, physicians will prescribe multiple products in order to get the best outcomes. It's called Poly pharmacy.

This latest product to enter the treatment of radiation will have little impact on the price of Plx R-18.

As we heard from Spidey, it is a good thing that there are multiple approaches to this deadly condition. This addition will only raise public awareness and thus great potential for all products to grow in this newly discovered vast market.